Weekly Insulin: A Step Forward, but What's Next for Indian Diabetes Care? The introduction of Novo Nordisk's Awiqli, a once a week basal insulin, marks a significant development in India's diabetes treatment.
With an estimated 101 million people living with diabetes and another 136 million at risk of developing the condition, India remains one of the world's largest diabetes hotspots.
Awiqli is part of a broader push by pharmaceutical companies to expand their product portfolios and tap into emerging markets. Novo Nordisk has already launched this product in over a dozen countries worldwide.